{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:14:23Z","timestamp":1790644463817,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Mantle cell lymphoma is a rare, typically aggressive B-cell non-Hodgkin lymphoma that often presents at an advanced stage and carries substantial long-term mortality despite therapeutic advances. Multiple clinical, biological, and treatment-related factors may influence survival in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the clinical characteristics, treatment patterns, and overall survival of patients with mantle cell lymphoma at a high-complexity referral center in a middle-income country.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort included adult patients diagnosed and managed at a high-complexity referral center in Colombia between January 2016 and October 2025. Overall survival was the primary outcome. Survival estimates were obtained using Kaplan\u2013Meier curves and compared with log-rank tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 41 patients were included, with 43.9% aged &amp;lt;65 years. Baseline clinical, laboratory, immunophenotypic, and cytological characteristics were similar across age groups, with most patients presenting with advanced disease, including Ann Arbor stage IV (66.7% vs. 72.3%) and high-risk MIPI classification (88.9% vs. 100%). First-line treatment differed by age, with younger patients more frequently receiving Nordic regimens and older patients receiving R-bendamustine; however, response rates were comparable. Overall survival did not differ significantly by sex, age group, Ann Arbor stage, or LDH levels. In contrast, MIPI category significantly predicted survival (log-rank p=0.017).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This real-world cohort describes patients with mantle cell lymphoma presenting predominantly with advanced-stage, high-risk disease. Treatment approaches differed by age, with comparable overall responses across groups. The findings suggest that prognostic indices and functional status assessment may aid outcome evaluation in routine practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1756632","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:26:55Z","timestamp":1769750815000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical characteristics, treatment patterns, and survival in mantle cell lymphoma: a real-world cohort"],"prefix":"10.3389","volume":"16","author":[{"given":"Cesar","family":"de la Hoz","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital Internacional de Colombia HIC- Fundaci\u00f3n Cardiovascular de Colombia FCV- Fundaci\u00f3n Universitaria FCV","place":["Piedecuesta, Santander, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Hurtado-Otiz","sequence":"additional","affiliation":[{"name":"Epidemiology Department, Hospital Internacional de Colombia HIC- Fundaci\u00f3n Cardiovascular de Colombia FCV- Fundaci\u00f3n Universitaria FCV","place":["Piedecuesta, Santander, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maricel","family":"Licht-Ardila","sequence":"additional","affiliation":[{"name":"Epidemiology Department, Hospital Internacional de Colombia HIC- Fundaci\u00f3n Cardiovascular de Colombia FCV- Fundaci\u00f3n Universitaria FCV","place":["Piedecuesta, Santander, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Cantillo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Internacional de Colombia HIC- Fundaci\u00f3n Cardiovascular de Colombia FCV- Fundaci\u00f3n Universitaria FCV","place":["Piedecuesta, Santander, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Silva","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Internacional de Colombia HIC- Fundaci\u00f3n Cardiovascular de Colombia FCV- Fundaci\u00f3n Universitaria FCV","place":["Piedecuesta, Santander, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leidy","family":"Herrera","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Internacional de Colombia HIC- Fundaci\u00f3n Cardiovascular de Colombia FCV- Fundaci\u00f3n Universitaria FCV","place":["Piedecuesta, Santander, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Internacional de Colombia HIC- Fundaci\u00f3n Cardiovascular de Colombia FCV- Fundaci\u00f3n Universitaria FCV","place":["Piedecuesta, Santander, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga Daniela","family":"Vega Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Internacional de Colombia HIC- Fundaci\u00f3n Cardiovascular de Colombia FCV- Fundaci\u00f3n Universitaria FCV","place":["Piedecuesta, Santander, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaiver","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Internacional de Colombia HIC- Fundaci\u00f3n Cardiovascular de Colombia FCV- Fundaci\u00f3n Universitaria FCV","place":["Piedecuesta, Santander, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Mendoza-Monsalve","sequence":"additional","affiliation":[{"name":"Epidemiology Department, Hospital Internacional de Colombia HIC- Fundaci\u00f3n Cardiovascular de Colombia FCV- Fundaci\u00f3n Universitaria FCV","place":["Piedecuesta, Santander, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhon Alexander","family":"Avila","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Internacional de Colombia HIC- Fundaci\u00f3n Cardiovascular de Colombia FCV- Fundaci\u00f3n Universitaria FCV","place":["Piedecuesta, Santander, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar Fabi\u00e1n","family":"Manrique-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Epidemiology Department, Hospital Internacional de Colombia HIC- Fundaci\u00f3n Cardiovascular de Colombia FCV- Fundaci\u00f3n Universitaria FCV","place":["Piedecuesta, Santander, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2013.13868","article-title":"Diagnosis and treatment of mantle cell lymphoma","volume":"143","author":"Hitz","year":"2013","journal-title":"Swiss Med Wkly"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/hematolrep16010006","article-title":"Survival outcomes of patients with mantle cell lymphoma: A retrospective, 15-year, real-life study","volume":"16","author":"Cencini","year":"2024","journal-title":"Hematol Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp495","article-title":"Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma","volume":"21","author":"Schaffel","year":"2010","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.021113","article-title":"Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting","volume":"95","author":"Van De Schans","year":"2010","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1182\/blood-2018-99-111471","article-title":"a swedish lymphoma registry study","volume":"132","year":"2018","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.770988","article-title":"Initial treatment patterns and survival outcomes of mantle cell lymphoma patients managed at chinese academic centers in the rituximab era: A real-world study","volume":"11","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/hon.2399","article-title":"The 2016 updated WHO classification of lymphoid neoplasias","volume":"35","author":"Quintanilla-Martinez","year":"2017","journal-title":"Hematol Oncol"},{"key":"B11","unstructured":""},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z","article-title":"Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors","volume":"82","author":"Bosch","year":"1998","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26306","article-title":"Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era","volume":"96","author":"Karmali","year":"2021","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3978\/j.issn.2304-3865.2014.11.03","article-title":"Staging and response assessment in lymphomas: the new Lugano classification","volume":"4","author":"Cheson","year":"2015","journal-title":"Chin Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2016.05.008","article-title":"The burden of non-Hodgkin lymphoma in Central and South America","volume":"44","author":"Diumenjo","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01977-y","article-title":"Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","volume":"37","author":"Scheubeck","year":"2023","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010757","article-title":"Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma","volume":"7","author":"Gerson","year":"2023","journal-title":"Blood Adv"},{"key":"B20","doi-asserted-by":"publisher","first-page":"11896","DOI":"10.1038\/s41598-021-91433-7","article-title":"Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma","volume":"11","author":"Jing","year":"2021","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001233","article-title":"SOX11-negative mantle cell lymphoma: clinicopathologic and prognostic features of 75 patients","volume":"43","author":"Xu","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet (Lon Eng)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized european MCL elderly trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"48692","DOI":"10.18632\/oncotarget.8961","article-title":"Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents","volume":"7","author":"Inamdar","year":"2016","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2021.10.001","article-title":"Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases","volume":"118","author":"Tashakori","year":"2021","journal-title":"Hum Pathol"},{"key":"B28","unstructured":""},{"key":"B29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/bmj.311.7003.485","article-title":"Absence of evidence is not evidence of absence","volume":"311","author":"Altman","year":"1995","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.177162","article-title":"Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment","volume":"103","author":"Rudelius","year":"2018","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1756632\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:26:57Z","timestamp":1771925217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1756632\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":30,"alternative-id":["10.3389\/fonc.2026.1756632"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1756632","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"article-number":"1756632"}}